Our Timeline

2017

May 1, 2017 Launch SND12, SND13 Trials

2016

Jan 29, 2016  Listed on Emerging Board, Taipei Stock Exchange

2015

Nov. 2015, SND12: Breakthrough Therapy Designation granted by USFDA

Combinational therapy for refractory schizophrenia

Oct. 2015. SND12: IND application approved by USFDA

Phase IIb/III trial of Combinational therapy for refractory schizophrenia

Jul, 2015 SND11: IND application approved by Taiwan FDA

Phase IIb/III trial of the new drug in adolescent schizophrenia

2014

Dec. 2014, SND13: Breakthrough Therapy Designation granted by USFDA

Add-on therapy of schizophrenia

Oct. 2014, SND13: IND application been approved by USFDA

Phase IIb/III trial Add-on therapy for schizophrenia

Aug. 2014, Ministry of Economic Affairs, A+ Industrial innovative R&D grant

Fast track clinical development

Apr. 2014, “Biotech and New Pharmaceutical Company” Approved by the Industrial Development Bureau, Ministry of Economic Affairs.

2013

Aug. 2013, SND11 IND approved by USFDA

Phase IIb/III clinical trial in adolescent schizophrenia

Apr. 201, 3 SyneuRx International (Taiwan) Corp. founded